Glusod

Glusod is an oral, prescription medication that contains the active ingredient empagliflozin, a sodium‑glucose co‑transporter‑2 (SGLT2) inhibitor. It is marketed in the European Union and is supplied as a tablet (strength not specified). Empagliflozin belongs to the antidiabetic therapeutic class and works by reducing renal glucose reabsorption, thereby helping to lower blood glucose levels in adults with type 2 diabetes mellitus and is intended for use under medical supervision.

Glusod is indicated for the management of hyperglycemia in adults diagnosed with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

- Used as monotherapy when metformin is not tolerated or contraindicated. - Combined with metformin or other oral antidiabetics to improve glycemic control. - May be added to insulin therapy for additional glucose lowering. - Considered for patients with established cardiovascular risk to provide renal and heart benefits. - Prescribed to help achieve individualized HbA1c targets.

The safety profile of Glusod reflects the pharmacology of empagliflozin, with adverse events that are generally mild but may include serious conditions that require medical attention. These events are reported in clinical studies and post‑marketing surveillance.

Common: - Increased urinary frequency and volume. - Mild genital mycotic infections in men and women. - Thirst or dry mouth. - Lower extremity edema. - Hypotension, particularly after the first dose. - Dizziness or light‑headedness, especially when standing quickly.

Serious: - Ketoacidosis (euglycemic) with symptoms such as nausea and rapid breathing. - Acute kidney injury, especially in patients with volume depletion. - Severe urinary tract infection requiring hospitalization. - Significant dehydration leading to electrolyte imbalance.

When prescribing Glusod, clinicians should evaluate patient-specific factors and monitor for conditions that could be worsened by SGLT2 inhibition. Renal function, volume status, and risk of ketoacidosis are particularly important considerations.

- Assess estimated glomerular filtration rate (eGFR) before initiation and periodically thereafter. - Avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). - Monitor for signs of dehydration, especially in the elderly or those on diuretics. - Counsel patients to maintain adequate fluid intake to reduce hypotension risk. - Discontinue if symptoms of ketoacidosis develop, even with modest glucose elevations. - Review concomitant use of insulin or sulfonylureas to prevent hypoglycemia.

Glusod can interact with several medicines that affect glucose metabolism, renal function, or blood pressure, requiring attention to dosing and monitoring.

Avoid: - Concomitant use with other SGLT2 inhibitors or potent diuretics that may cause excessive volume depletion. - Combination with strong CYP3A4 inhibitors if they alter empagliflozin exposure (though minimal metabolism, caution is advised).

Use with caution: - Insulin or sulfonylureas, as the risk of hypoglycemia may increase. - Loop or thiazide diuretics, which can amplify dehydration and hypotension. - NSAIDs or other nephrotoxic agents, which may worsen renal function.